CD274 and neoplasm: We report here that novel anti-CTLA-4 and anti-PD-L1 immunomodulatory mAbs, previously generated in our laboratory, have greater anti-tumor activity than the clinically validated ipilimumab and atezolizumab on TNBC cells, well known for their aggressiveness and resistance to conventional chemotherapeutic treatments.